EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieVergleichsstudie

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

Vania Hungria, Pawel Robak, Marek Hus, Vera Zherebtsova, Christopher Ward, P Joy Ho, Ana Carolina Ribas de Almeida, Roman Hajek, Kihyun Kim, Sebastian Grosicki, Hanlon Sia, Adam Bryant und 29 weitere

New England Journal of Medicine · 01.08.2024 · 391 (5) · 393-407

DOI: 10.1056/nejmoa2405090 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 01.08.2024. Verfasst von Vania Hungria und 40 weiteren Autor:innen. Beteiligte Einrichtung: From Clinica São Germano (V.H.) and Hospital das Clínicas and Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo (G.A.M.), São Pau…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Bortezomib, Dexamethasone, Multiple Myeloma. Die Arbeit wurde bisher 208-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: GlaxoSmithKline.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBortezomibDexamethasoneMultiple MyelomaProgression-Free SurvivalAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedKaplan-Meier EstimateNeoplasm, ResidualDisease Progression

Substanzen

Antibodies, MonoclonalAntibodies, Monoclonal, Humanizedbelantamab mafodotinBortezomibdaratumumabDexamethasone

Autor:innen und Institutionen

  • From Clinica São Germano (V.H.) and Hospital das Clínicas and Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo (G.A.M.), São Paulo, Centro de Pesquisa e Ensino em Saúde de Santa Catarin, Florianópol…

ORCID-Profile: Marcelo Pitombeira de Lacerda, Claudio Cerchione, Nick Pirooz

Förderung

  • GlaxoSmithKline

Zitieren

APA

Hungria, V., Robak, P., Hus, M., Zherebtsova, V., Ward, C., Ho, P. J., Ribas de Almeida, A. C., Hajek, R., Kim, K., Grosicki, S., Sia, H., Bryant, A., Pitombeira de Lacerda, M., Aparecida Martinez, G., Sureda Balarí, A. M., Sandhu, I., Cerchione, C., Ganly, P., Dimopoulos, M., …, & DREAMM-7 Investigators (2024). Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 391(5), 393-407. https://doi.org/10.1056/nejmoa2405090

Vancouver

Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, et al. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine. 2024;391(5):393-407. doi:10.1056/nejmoa2405090

BibTeX
@article{Hungria2024,
  author = {Hungria, Vania and Robak, Pawel and Hus, Marek and Zherebtsova, Vera and Ward, Christopher and Ho, P Joy and Ribas de Almeida, Ana Carolina and Hajek, Roman and Kim, Kihyun and Grosicki, Sebastian and Sia, Hanlon and Bryant, Adam and Pitombeira de Lacerda, Marcelo and Aparecida Martinez, Gracia and Sureda Balarí, Anna Maria and Sandhu, Irwindeep and Cerchione, Claudio and Ganly, Peter and Dimopoulos, Meletios and Fu, Chengcheng and Garg, Mamta and Abdallah, Al-Ola and Oriol, Albert and Gatt, Moshe E and Cavo, Michele and Rifkin, Robert and Fujisaki, Tomoaki and Mielnik, Michał and Pirooz, Nick and McKeown, Astrid and McNamara, Simon and Zhou, Xiangdong and Nichols, Maureen and Lewis, Eric and Rogers, Rachel and Baig, Hena and Eccersley, Lydia and Roy-Ghanta, Sumita and Opalinska, Joanna and Mateos, María-Victoria and DREAMM-7 Investigators, DREAMM-7 Investigators},
  title = {Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {391},
  number = {5},
  pages = {393--407},
  doi = {10.1056/nejmoa2405090}
}
Kostenlos starten →